-

Opentrons Partners With Zymo Research To Offer an Affordable, Automated COVID-19 Testing Platform

BROOKLYN, N.Y.--(BUSINESS WIRE)--Zymo Research Corp, a California-based life science reagent company and Opentrons Labworks, Inc, makers of affordable and easy-to-use lab robotics, have partnered to create a robust engine for SARS-CoV-2 molecular testing.

As the COVID-19 crisis persists, the need for high-throughput, fast turn-around, and affordable testing platforms will become a matter of vital security to facilitate routine testing for communities around the world. The automated RNA extraction pipeline created with the Opentrons OT-2 liquid handling robot, verified labware, and magnetic module together with Zymo Research’s Quick-DNA/RNA Viral MagBead Kit can serve as the foundation for any lab seeking to perform high-sensitivity SARS-CoV-2 testing.

“The pairing of technologies from Opentrons and Zymo Research establishes a new, automated RNA extraction solution at a time when the legacy suppliers are unable to keep up with demand,” said Will Canine, co-founder and CPO at Opentrons. “We are proud to be able to bring this affordable, easy-to-use system to the market very quickly in partnership with Zymo Research.”

Additionally, any OT-2 robot user can download open-source scripts to automate Quick-DNA/RNA Viral MagBead Kit to perform the protocol in their own lab. These are the same protocols being used in CLIA labs developing tests to be run in anticipation of FDA EUA.

”Our country and this world are in a time of need. Zymo Research is doing whatever it takes to ensure that products relating to COVID-19 testing are getting to those labs and companies working on the front lines. We are proud to partner with a company like Opentrons to produce a simple solution that facilitates much-needed testing,” said Marc Van Eden, PhD, Vice President of Business Development at Zymo Research.

To learn more about the Opentrons COVID-19 Testing System, email covid-19@opentrons.com.

About Zymo Research Corp.

Zymo Research is a privately owned company that has been serving the scientific community with state-of-the-art molecular biology tools since 1994. “The Beauty of Science is to Make Things Simple” is their motto, which is reflected in every product they produce, from their epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, and NGS technologies that are high quality and simple to use. To learn more visit www.zymoresearch.com.

About Opentrons

Opentrons makes automation accessible for any lab, starting with affordable pipetting robots for biologists. With its easy-to-use hardware and an open software platform, Opentrons automates manual lab work and empowers collaborative research for life scientists. Opentrons has helped over 1,500 labs in 45 countries save time, money and lab costs—including 47 of the top 50 academic universities in the world such as MIT, Oxford, and Stanford, and 9 of the top 10 pharmaceutical companies such as GSK, Merck, and Novartis. To learn more, visit opentrons.com.

Contacts

Laurie Vazquez
press@opentrons.com

More News From Opentrons and Zymo Research

Pandemic Response Lab Detects First Omicron Cases in New York City

NEW YORK--(BUSINESS WIRE)--Pandemic Response Lab (PRL), part of Opentrons Labworks Inc., reported the discovery of the first four Omicron cases in New York City. The announcement was made by Governor Kathy Hochul and Mayor Bill de Blasio on Thursday evening.1 This underscores the importance of fast and accurate testing and sequencing as part of the mitigation strategy to further contain the spread of new variants of concern. “PRL is committed to a coordinated response with public health officia...

Opentrons Announces $200 Million Series C Round Led by SoftBank Vision Fund 2

NEW YORK--(BUSINESS WIRE)--Today Opentrons Labworks Inc. has announced SoftBank Vision Fund 2* has led the company’s $200 million Series C investment with participation by Khosla Ventures. Opentrons will use this fundraising round to further invest in its automated lab platform globally. “Biology opens the door to solve many of humanity’s grand challenges. For far too long, scientists and clinicians have been locked-in by slow, expensive, and overly complex lab solutions that underpin their wor...

Pandemic Response Lab and Brio Announce Partnership to Provide Innovative Molecular Diagnostics Testing Solutions for the Entertainment Industry

NEW YORK & BOSTON--(BUSINESS WIRE)--The Pandemic Response Lab (PRL) and Brio today announced they are partnering to provide COVID-19 testing and variant “zone” surveillance tracking to mitigate the risk of new and emerging variants for the entertainment industry. The partnership will deliver fast, low-cost, end-to-end testing solutions to help ensure the safety of cast and crew members while reducing costs and production downtime. Under the partnership, Brio’s platform will act as the operating...
Back to Newsroom